Cargando…

Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening-Detected Lung Cancers

BACKGROUND: The issue of overdiagnosis in low-dose computed tomography (LDCT) screening trials could be addressed by the development of complementary bio-markers able to improve detection of aggressive disease. The mutation profile of LDCT screening–detected lung tumors is currently unknown. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verri, Carla, Borzi, Cristina, Holscher, Todd, Dugo, Matteo, Devecchi, Andrea, Drake, Katherine, Sestini, Stefano, Suatoni, Paola, Romeo, Elisa, Sozzi, Gabriella, Pastorino, Ugo, Boeri, Mattia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832691/ https://www.ncbi.nlm.nih.gov/pubmed/28302568 http://dx.doi.org/10.1016/j.jtho.2017.03.001

Ejemplares similares

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
por: Mensah, Mavis, et al.
Publicado: (2017)

Assessment of Circulating microRNAs in Plasma of Lung Cancer Patients
por: Fortunato, Orazio, et al.
Publicado: (2014)

Novel method to detect microRNAs using chip-based QuantStudio 3D digital PCR
por: Conte, Davide, et al.
Publicado: (2015)

Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening
por: Sestini, Stefano, et al.
Publicado: (2015)

Correction: Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening
por: Sestini, Stefano, et al.
Publicado: (2019)

MicroRNA Profile of Lung Tumor Tissues Is Associated with a High Risk Plasma miRNA Signature
por: Fortunato, Orazio, et al.
Publicado: (2016)

Inflammatory status and lung function predict mortality in lung cancer screening participants
por: Pastorino, Ugo, et al.
Publicado: (2018)

Timeline of SARS-CoV-2 Spread in Italy: Results from an Independent Serological Retesting
por: Montomoli, Emanuele, et al.
Publicado: (2021)

Development of a Molecular Blood-Based Immune Signature Classifier as Biomarker for Risks Assessment in Lung Cancer Screening
por: Fortunato, Orazio, et al.
Publicado: (2022)

Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy
por: Apolone, Giovanni, et al.
Publicado: (2020)

Therapeutic Use of MicroRNAs in Lung Cancer
por: Fortunato, Orazio, et al.
Publicado: (2014)

Feasibility and Safety of Lung Cancer Screening and Prevention Program During the COVID-19 Pandemic
por: Milanese, Gianluca, et al.
Publicado: (2021)

Improved Prognostic Prediction in Never-Smoker Lung Cancer Patients by Integration of a Systemic Inflammation Marker with Tumor Immune Contexture Analysis
por: Milione, Massimo, et al.
Publicado: (2020)

Author Correction: Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness
por: Moro, Massimo, et al.
Publicado: (2018)

Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness
por: Moro, Massimo, et al.
Publicado: (2017)

MiR-486-5p Targets CD133+ Lung Cancer Stem Cells through the p85/AKT Pathway
por: Moro, Massimo, et al.
Publicado: (2022)

Circulating mir‐320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk
por: Fortunato, Orazio, et al.
Publicado: (2019)

A Cross-Comparison of High-Throughput Platforms for Circulating MicroRNA Quantification, Agreement in Risk Classification, and Biomarker Discovery in Non-Small Cell Lung Cancer
por: Gargiuli, Chiara, et al.
Publicado: (2022)

c-Myc shuttled by tumour-derived extracellular vesicles promotes lung bronchial cell proliferation through miR-19b and miR-92a
por: Borzi, Cristina, et al.
Publicado: (2019)

Cotargeting of miR‐126‐3p and miR‐221‐3p inhibits PIK3R2 and PTEN, reducing lung cancer growth and metastasis by blocking AKT and CXCR4 signalling
por: Di Paolo, Daniela, et al.
Publicado: (2021)

Extracellular vesicles from subjects with COPD modulate cancer initiating cells phenotype through HIF-1α shuttling
por: Petraroia, Ilaria, et al.
Publicado: (2023)

Gene Signatures Stratify Computed Tomography Screening Detected Lung Cancer in High-Risk Populations()
por: Hu, Jiangting, et al.
Publicado: (2015)

Risk Assessment of Early Lung Cancer with LDCT and Health Examinations
por: Chang, Hou-Tai, et al.
Publicado: (2022)

Influencing factors of LDCT recommendation by physicians in Sichuan Province, China
por: Li, Ruicen, et al.
Publicado: (2023)

C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis
por: Leuzzi, Giovanni, et al.
Publicado: (2017)

LDCT lung cancer screening in populations at different risk for lung cancer
por: Teles, Gustavo Borges da Silva, et al.
Publicado: (2020)

LDCT Screening in Smokers in India—A Pilot, Proof-of-Concept Study
por: Parang, Sanghavi, et al.
Publicado: (2021)

Variability of [(18)F]FDG-PET/LDCT reporting in vascular graft and endograft infection
por: Liesker, David J., et al.
Publicado: (2023)

Circulating extracellular vesicles from individuals at high-risk of lung cancer induce pro-tumorigenic conversion of stromal cells through transfer of miR-126 and miR-320
por: Pontis, Francesca, et al.
Publicado: (2021)

Peripheral interstitial lung abnormalities on LDCT in an asymptomatic, nonsmoking Chinese urban cohort
por: Gao, Zhimei, et al.
Publicado: (2023)

Exo-miRNAs as a New Tool for Liquid Biopsy in Lung Cancer
por: Fortunato, Orazio, et al.
Publicado: (2019)

Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction
por: Fortunato, O, et al.
Publicado: (2014)

Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy
por: Pastorino, U, et al.
Publicado: (2019)

Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy
por: Pastorino, U, et al.
Publicado: (2019)

YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes
por: Lorenzetto, Erica, et al.
Publicado: (2014)

Evaluation of Simplified Diet Scores Related to C-Reactive Protein in Heavy Smokers Undergoing Lung Cancer Screening
por: Sabia, Federica, et al.
Publicado: (2022)

Artificial neural networks improve LDCT lung cancer screening: a comparative validation study
por: Hsu, Yin-Chen, et al.
Publicado: (2020)

Predicting malignancy: subsolid nodules detected on LDCT in a surgical cohort of East Asian patients
por: Wang, Yung-Hsien, et al.
Publicado: (2020)

EFFECTIVENESS OF SMOKING CESSATION INTERVENTIONS WITH LDCT LUNG CANCER SCREENING AMONG AFRICAN AMERICAN SMOKERS
por: Tseng, Tung-Sung, et al.
Publicado: (2022)

Differential eligibility of African American and European American lung cancer cases using LDCT screening guidelines
por: Ryan, Bríd M
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_12mjpdmi1bfv6g9otp5c1hjaoe